Shineco, Inc. Reports Fiscal Year 2020 Financial Results

Rhea-AI Summary

Shineco reported fiscal year 2020 results, with revenues at $23.68 million, a 24.1% decline from $31.22 million in FY 2019. The company experienced a net loss of $6.63 million, compared to a net income of $0.80 million the previous year. Gross profit decreased by 31.8% to $6.12 million, with gross margin falling to 25.8%. The decline in revenue was attributed to a significant drop in sales across all product lines, exacerbated by the impacts of COVID-19. Despite this, Shineco is pursuing a strategic plan integrating industrial hemp and exploring biomedical investment opportunities.

Positive

• The company is pursuing a strategic plan integrating the entire industrial chain of industrial hemp.
• Shineco is exploring investment opportunities in the biomedical field.

Negative

• Revenue fell by 24.1% to $23.68 million, down from $31.22 million in FY 2019.
• Net loss increased to $6.63 million, compared to a net income of $0.80 million last year.
• Gross profit decreased by 31.8% to $6.12 million, with overall gross margin declining to 25.8%.

BEIJING, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: TYHT), a producer and distributor of Chinese herbal medicines, organic agricultural and hemp products, as well as various health and well-being-focused plant-based products in China, announced today its financial results for the fiscal year ended June 30, 2020.

Mr. Guocong Zhou, Chief Executive Officer of Shineco, commented, “In fiscal 2020, we achieved a revenue of USD23.68 million and a net loss of $6.63 million. Overall, our various financial indicators have experienced a significant decline, mainly due to the Company's business transformation and the impact of COVID-19. At present, the Company has formed a strategic plan integrating the entire industrial chain of industrial hemp. At the same time, the Company is also actively looking for investment opportunities in the biomedical field. I believe that as we gradually implement our projects, we will achieve success in the next fiscal year.”

Fiscal Year 2020 Financial Highlights

• Revenue: $23.68 million (at 25.8% gross margin), down 24.1% from $31.22 million (at 28.7% gross margin) in fiscal year 2019, reflecting the decrease in sales across all products.
• Gross profit: $6.12 million, down 31.8% from $8.97 million in fiscal year 2019.
• Operating income (loss): a loss of $3.49 million, compared to income of $0.12 million in fiscal year 2019.
• Net income (loss) attributable to Shineco: a loss of $6.63 million, compared to an income of $0.80 million in fiscal year 2019.
• Earnings (Loss) per share: basic and diluted loss per share of 2.25, compared to basic and diluted earnings per share of $0.32 in fiscal year 2019.

Fiscal Year 2020 Financial Results

Revenue

Revenue for the fiscal year ended June 30, 2020 decreased by $7.54 million, or 24.1%, to $23.68 million from $31.22 million for the same period in 2019, mainly due to the decrease in sales across all products. 

		For the Fiscal Years Ended June 30
		2020												2019
($ millions)		Revenue				COGS				Gross Margin				Revenue				COGS				Gross Margin
Luobuma products			0.17				0.25				-46.0	%			0.66				0.30				54.0	%
Chinese medicinal herbal products			13.27				10.04				24.3	%			13.71				10.34				24.6	%
Other agricultural products			10.25				7.28				29.0	%			16.85				11.61				31.1	%
Total			23.68				17.56				25.8	%			31.22				22.25				28.7	%

Revenue from Luobuma products decreased by $0.49 million, or 74.6%, to $0.17 million for the year ended June 30, 2020 from $0.66 million for the same period in 2019, mainly due to the decrease in revenue from Tenet-Jove and Tenet Huatai. Since the beginning of the year, we did not launch new products, and we mainly focused on clearing off our old stocks. In addition, our sales of Luobuma products were affected by the COVID-19 outbreak, as a result, sales decreased during the year ended June 30, 2020 as compared to the same period in 2019.

Revenue from Chinese medicinal herbal products decreased slightly by $0.44 million, or 3.2%, to $13.27 million for the fiscal year ended June 30, 2020 from $13.71 million for the same period last year. The sales of Chinese medicinal herbal products were comparatively stable during the fiscal year ended June 30, 2020 as compared to the same period in 2019. The decrease was mainly due to the depreciation of RMB against US$. The average translation rate for the years ended June 30, 2020 and 2019 were at 1 RMB to 0.1422 USD and at 1 RMB to 0.1466 USD, respectively, which represented a decrease of 2.97%.

Revenue from other agricultural products decreased by $6.60 million, or 39.2%, to $10.25 million for the fiscal year ended June 30, 2020 from $16.85 million for the same period in 2019. The decrease was mainly due to the decline of sales volume of yew trees during the second half of fiscal year ended June 30, 2020 as compared to the same period in 2019. Our sales of yew trees were affected by the COVID-19 outbreak, which resulted in less orders from our customers during the year ended June 30, 2020.

Gross profit and Gross Margin

Total cost of revenue decreased by $4.68 million, or 21.05%, to $17.56 million for the fiscal year ended June 30, 2020 from $22.25 million for the same period in 2019. Gross profit decreased by $2.85 million, or 31.8%, to $6.12 million for the fiscal year ended June 30, 2020 from $8.97 million for the same period in 2019. Overall gross margin decreased by 2.9 percentage points to 25.8% for the fiscal year ended June 30, 2020, compared to 28.7% for the same period in 2019.

Gross margins for Luobuma products, Chinese medicinal herbal products, and other agricultural products were negative 46.0%, and 24.3% and 29.0%, respectively, for the fiscal year ended June 30, 2020. This compared to gross margins for Luobuma products, Chinese medicinal herbal products, and other agricultural products of 54.0%, 24.6%, and 31.1%, respectively, for the same period in 2019.

Operating income

General and administrative expenses increased by $1.07 million, or 13.1%, to $9.22 million for the fiscal year ended June 30, 2020 from $8.15 million for the same period in 2019. The increase in general and administrative expenses was mainly due to an increase in bad debt expense of US$ 338,537, an increase in staff salary expenses due to the issuance of restricted shares to the management as compensation of US$ 1,022,660, as well as an increased general and administrative expenses of US$ 315,453 for our newly established entity TNB. The increase was partially offset by the decreased offering cost write-off of US$ 434,000. The US$ 434,000 was the valuation of the Commitment Shares retained by IFG Fund upon termination of the Purchase Agreement and Registration Rights Agreement during the year ended June 30, 2019.

Selling expenses decreased by $0.32 million, or 45.1%, to $0.39 million for the fiscal year ended June 30, 2020 from $0.70 million for the same period in 2019. The decrease was primarily due to the decrease in advertising expense, commission expenses as well as shipping expenses of Tenet-Jove which was in line with the decrease in our sales during the year ended June 30, 2020. The decrease was also due to the decrease in salary related expenses as a result of reduced number of staff during the year ended June 30, 2020.

Operating loss was $3.49 million for the fiscal year ended June 30, 2020, compared to operating income of $0.12 million for the same period in 2019.

Net income (loss)

Net loss was $6.51 million for the fiscal year ended June 30, 2020, compared to net income of $0.88 million for the same period in 2019. After the deduction of non-controlling interests, net loss attributable to common shareholders for the fiscal year ended June 30, 2020 was $6.63 million, or $2.25 per basic and diluted share. This compare to net income attributable to common shareholders of $0.80 million, $0.32 per basic and diluted share, for the same period in 2019.

Financial Condition

As of June 30, 2020, the Company had cash and cash equivalents of $32.37 million, compared to $35.33 million as of June 30, 2019. Net cash used in operating activities was $4.66 million for the fiscal year ended June 30, 2020, compared to net cash provided by operation activities of $3.50 million for the same period in 2019. Net cash provided by investing activities was $0.10 million for the fiscal year ended June 30, 2020, compared to net cash used in investing activities of $0.25 million for the same period in 2019. Net cash provided by financing activities was $2.63 million for the fiscal year ended June 30, 2020, compared to $1.81 million for the same period in 2019.

About Shineco, Inc.

Incorporated in Delaware in August 1997 and headquartered in Beijing, China, Shineco is a holding company. Through its subsidiaries and variable interest entities, Shineco undertakes vertically- and horizontally-integrated production, distribution, and sales channels to provide health and well-being focused plant-based products in China. Utilizing modern engineering technologies and biotechnologies, Shineco produces, among other products, Chinese herbal medicines, organic agricultural produce, and specialized textiles. For more information about Shineco, please visit http://tianyiluobuma.com.

Forward-Looking Statements

This press release contains information about Shineco's view of its future expectations, plans and prospects that constitute forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, the impact of the COVID-19 pandemic, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. Shineco encourages you to review other factors that may affect its future results in Shineco's registration statement and in its other filings with the Securities and Exchange Commission, including the risks described under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our annual report on Form 10-K for the fiscal year ended June 30, 2020. The forward-looking statements in this press release are based on current expectations and Shineco assumes no obligation to update these forward-looking statements.

For more information, please contact:

Tina Xiao
Ascent Investor Relations LLC
Phone: +1-917-609-0333
Email: tina.xiao@ascent-ir.com

SHINECO, INC.
CONSOLIDATED BALANCE SHEETS

		June 30,				June 30,
		2020				2019
ASSETS
CURRENT ASSETS:
Cash		$	32,371,372			$	35,330,676
Accounts receivable, net			11,008,485				9,683,074
Due from related parties			120,939				188,453
Inventories, net			1,799,876				2,215,559
Advances to suppliers, net			13,313,946				11,833,994
Other current assets			905,380				1,710,619
TOTAL CURRENT ASSETS			59,519,998				60,962,375
Property and equipment, net			9,489,484				10,667,730
Land use right, net of accumulated amortization			1,195,943				1,264,309
Investments			4,515,124				6,650,944
Distribution rights			1,043,887				1,074,736
Long-term deposit and other noncurrent assets			96,280				103,864
Right of use assets			3,227,895				-
Prepaid leases			-				2,857,344
Deferred tax assets			-				158,171
TOTAL ASSETS		$	79,088,611			$	83,739,473
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Short-term loans		$	2,333,894			$	2,410,147
Accounts payable			148,209				220,119
Advances from customers			6,324				382,091
Due to related parties			1,355,919				234,500
Other payables and accrued expenses			4,018,684				3,893,027
Operating lease liabilities - current			97,633				-
Taxes payable			3,386,662				3,341,872
TOTAL CURRENT LIABILITIES			11,347,325				10,481,756
Income tax payable - noncurrent portion			566,022				625,603
Operating lease liabilities - non-current			401,891				-
Deferred tax liability

FAQ

What were Shineco's revenue and net loss for the fiscal year ended June 30, 2020?

Shineco reported revenue of $23.68 million and a net loss of $6.63 million for the fiscal year ended June 30, 2020.

How much did Shineco's revenue decline compared to the previous fiscal year?

Shineco's revenue declined by 24.1% from $31.22 million in FY 2019 to $23.68 million in FY 2020.

What was Shineco's gross profit and margin for FY 2020?

In FY 2020, Shineco's gross profit was $6.12 million with a gross margin of 25.8%.

How did COVID-19 impact Shineco's sales in FY 2020?

COVID-19 significantly affected Shineco's sales performance across all product lines, contributing to the overall revenue decline.

What future strategies is Shineco considering after reporting FY 2020 results?

Shineco is forming a strategic plan integrating industrial hemp and looking for investment opportunities in the biomedical field.